BioNexus Gene Lab (BGLC) Restructuring Costs (2020 - 2025)

BioNexus Gene Lab (BGLC) has 6 years of Restructuring Costs data on file, last reported at $181095.0 in Q4 2025.

• For the quarter ending Q4 2025, Restructuring Costs rose 9.14% year-over-year to $181095.0; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (down 16.23% YoY), and the FY2025 full-year result was $1.5 million, down 16.23% from the prior year.
• Restructuring Costs slipped to $181095.0 in Q4 2025, from $445691.0 in the prior quarter.
• In the past five years, Restructuring Costs ranged from a high of $3.1 million in Q3 2023 to a low of -$2.0 million in Q4 2023.
• A 5-year average of $440918.4 and a median of $432257.5 in 2022 frame the typical range for Restructuring Costs.
• Across the five-year window, Restructuring Costs jumped 5449.25% in 2021 and slumped 506.52% in 2023, its largest moves.
• Tracing BGLC's Restructuring Costs over 5 years: stood at $1.2 million in 2021, then slumped by 58.01% to $487858.0 in 2022, then tumbled by 506.52% to -$2.0 million in 2023, then soared by 108.37% to $165932.0 in 2024, then grew by 9.14% to $181095.0 in 2025.
• Business Quant data shows BGLC's Restructuring Costs at $181095.0 in Q4 2025, $445691.0 in Q3 2025, and $516790.0 in Q2 2025.